Automation of the In Vitro Fertilization Laboratory: A Validation Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Autonomy
研究概览
简要总结
Enrolled patients will undergo an Assisted Reproductive technology (ART) treatment using intracytoplasmic sperm injection (ICSI, the direct injection of a single sperm cell into an oocyte) as the method of insemination. In this prospective cohort study, patients' sperm, eggs, and embryos will be processed using an automated system called AURA (Conceivable Life Sciences), which consists of five subsystems. Specifically, sperm samples will be prepared for fertilization using the subsystem C:SPERM. Cumulus-oocyte complexes (COCs) containing the oocytes will be isolated from follicular fluid using the subsystem C:EGG. One out of every four COCs will be removed from the AURA system at random and processed according to the local treatment clinic's standard operating procedure. All other COCs will continue automated procedures and will be denuded, fertilized, incubated, and vitrified using the AURA subsystems C:EGG. C:ICSI, C:CULTURE and C:VIT, respectively. All automated procedures will be conducted under the supervision of a laboratory manager, who can intervene, address any potential anomalies, and override any steps undertaken by the automated AURA system. The study aims to deliver a descriptive evaluation of the AURA system, including assessing the device's performance, defined by its level of automation, efficiency, and throughput. As a secondary objective, the study aims to characterize the clinical performance of each of AURA's subsystems and correlate this performance against pre-established benchmarks in a non-inferiority statistical analysis. Finally, the study seeks to collect technical data related to AURA's hardware and software operation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent signed by the patients before treatment.
- •Medical indication to perform assisted reproductive technology.
- •Body mass index between 20 and 29 kg/m2 (female participants only).
- •For women with indication of utilizing autologous eggs:
- •Anti-Müllerian Hormone (AMH) value of at least 1.5 ng/mL.
- •18 - 39 years of age.
- •For women utilizing donor eggs (egg donor age 18-28 years):
- •18 - 45 years of age.
排除标准
- •Patients diagnosed with recurrent pregnancy loss.
- •Inaccessible ovaries for puncture.
- •History of total or partial fertilization failure in a previous fertility treatment.
- •History of repeated implantation failure defined as three previous unsuccessful embryo transfers.
- •Uterine factors (e.g. fibroids, uterine surgeries, Müllerian malformations) at the discretion of the medical team and based on its impact on success and/or risk to the patient or the pregnancy may compromise treatment prognosis).
- •Untreated hydrosalpinx
- •Severe endometriosis III, IV, presence of endometriomas and/or history of endometrioma resection.
- •Polycystic ovarian syndrome.
- •Patients with any of the following severe male factor infertility:
- •Sperm concentrations less than 5 million per mL
- •Progressive motility less than 5%
- •Others (e.g, globozoospermia and seminal infections) at the discretion of the medical team and based on its impact on success.
- •Surgically retrieved sperm (TESE, MESA, PESA)
- •Pre-existing conditions compromising reproductive (e.g., thrombophilia, chronic degenerative and autoimmune diseases, uncontrolled hormonal disorders).
- •Any other case of abnormalities that could compromise success rates according to the criteria of clinical personnel in charge.
- •Inability to adhere to the medical protocols and/or schedules for personal reasons.
- •Intercurrent medical disorder
研究组 & 干预措施
AURA assisted ART treatment
The laboratory element of the patient's ART treatment will be automated through the use of the AURA device. This includes sperm preparation and egg retrieval from follicular fluid. 1 out of every 4 eggs will be randomly removed from the AURA system and treated by standard care. The remaining eggs will be maintained in the AURA system and further processed automatically for egg denudation, fertilization, embryo culture, embryo cryopreservation.
干预措施: AURA assisted ART treatment (Device)
结局指标
主要结局
Autonomy
时间窗: 9 months
proportion of tasks successfully completed by the AURA system without requiring human intervention.
Procedural timings
时间窗: 9 months
time employed by the AURA system to complete each of its automated tasks.
次要结局
- Sperm motility post preparation(9 months)
- Denudation survival rate(9 months)
- ICSI damage rate(9 months)
- Normal fertilization rate(9 months)
- Blastocyst development rate(9 months)
- Usable blastocyst development rate(9 months)
- Blastocyst cryosurvival rate(9 months)
- Implantation rate(9 months)
- Clinical pregnancy rate(9 months)